



**[Billing Code Update](#)**

TUESDAY, JUNE 30, 2020

North Carolina Medicaid has received calls concerning claim denials for some services provided by nurse practitioners and physician assistants.

[More](#)

**[SPECIAL BULLETIN COVID-19 #103: Telehealth and Virtual Patient Communications Clinical Policy Modifications - Nursing Facility Care](#)**

THURSDAY, JUNE 25, 2020

This bulletin replaces SPECIAL BULLETIN COVID-19 #79 in its entirety. NC Medicaid has temporarily modified its Telemedicine and Telepsychiatry Clinical Coverage Policy to better enable the delivery of remote care to Medicaid beneficiaries.

[More](#)

**[SPECIAL BULLETIN COVID-19 #102: Laboratory Codes for Coronavirus \(COVID-19\) Testing](#)**

MONDAY, JUNE 22, 2020

The Centers for Medicare & Medicaid Services (CMS) and the American Medical Association have announced the release of several new codes to report testing for active cases of Coronavirus (COVID-19) as well as detection of antibodies.

[More](#)

**[SPECIAL BULLETIN COVID-19 #101: Medicaid Providers May Be Eligible for Federal Funding](#)**

FRIDAY, JUNE 19, 2020

CARES Act Provider Relief Fund Webcast, Information for Medicaid Providers and a Checklist for Medicaid Providers Eligible for Federal Relief.

[More](#)

**[Emapalumab-lzsg Injection, for Intravenous Use \(Gamifant™\) HCPCS code J9210: Billing Guidelines](#)**

TUESDAY, JUNE 16, 2020

Effective with date of service Dec. 28, 2019, the Medicaid and NC Health Choice programs cover emapalumab-lzsg injection, for intravenous use (Gamifant™) for use in the Physician Administered Drug Program (PADP) outpatient hospital setting (only) when billed with HCPCS code J9210 - Injection, emapalumab-lzsg, 1 mg.

[More](#)



**[Meloxicam Injection, for Intravenous Use \(Anjeso™\) HCPCS Code J3490: Billing Guidelines](#)**

TUESDAY, JUNE 16, 2020

Effective with date of service April 7, 2020, the Medicaid and NC Health Choice programs cover meloxicam injection, for intravenous use (Anjeso™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J3490 - Unclassified drugs.

[More](#)

**[Sacituzumab Govitecan-hziy for Injection, for Intravenous Use \(Trodelvy™\) HCPCS Code J9999: Billing Guidelines](#)**

TUESDAY, JUNE 16, 2020

Effective with date of service April 23, 2020, the Medicaid and NC Health Choice programs cover sacituzumab govitecan-hziy for injection, for intravenous use (Trodelvy™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs.

[More](#)

**[SPECIAL BULLETIN COVID-19 #100: Hospice Provider COVID-19 Rate Structure Clarifications](#)**

MONDAY, JUNE 15, 2020

NC Medicaid has implemented COVID-19 rate increase functionality to reimburse hospice care provided in a skilled nursing facility (SNF) designated as a "SNF COVID-Outbreak site" or "SNF COVID-Response site" in a ratio consistent with how hospice care is reimbursed in all other SNFs.

[More](#)

**[SPECIAL BULLETIN COVID-19 #99: North Carolina General Assembly Mandates Temporary 5% Rate Increase for Certain Medicaid Providers](#)**

MONDAY, JUNE 15, 2020

Per Section 4.6 of the North Carolina General Assembly's recently approved Session Law 2020-4 (House Bill 1043), NC Medicaid is implementing a 5% rate increase for all Fee-For-Service (FFS) Medicaid providers who had not yet received a 5% increase during the COVID-19 public health emergency.

[More](#)



**[SPECIAL BULLETIN COVID-19 #98: COVID-19 Knowledge Center Now Available: A Convenient Way for Providers to Find Information](#)**

THURSDAY, JUNE 11, 2020

Medicaid and NC Health Choice providers now have a single source to find answers to questions about COVID-19. The online resource is a collection of Medicaid and behavioral health COVID-19 information, including answers to questions received in the COVID-19 mailbox, during webinars, from COVID-19 Special Medicaid Bulletins and other sources.

[More](#)

**[SPECIAL BULLETIN COVID-19 #97: Webinar Update for Behavioral Health and I/DD Providers](#)**

WEDNESDAY, JUNE 10, 2020

Panelists will present a structured PowerPoint presentation focused on Appendix K and Retention Payments for the Innovations Waiver on Thursday, June 11, 2020, at 3 p.m.

[More](#)

**[SPECIAL BULLETIN COVID-19 #96: Clinician and Laboratory Guidance Including Testing and Supplies](#)**

TUESDAY, JUNE 9, 2020

North Carolina is experiencing increased community transmission of COVID-19 in many areas of the state, particularly among our historically marginalized populations, especially our Latinx community. Pre-symptomatic and asymptomatic spread is playing an important role. Updated clinician and laboratory testing guidance and a new resource on community testing in historically marginalized populations are available.

[More](#)

**[Tailored Care Management Update](#)**

TUESDAY, JUNE 9, 2020

In December 2019, DHHS released the draft Tailored Care Management Provider Manual and application questions for providers interested in becoming Advanced Medical Home Plus practices or Care Management Agencies. The Department received many thoughtful comments on the draft Provider Manual and has made several updates.

[More](#)



**[Trastuzumab-dttb for Injection, for Intravenous Use \(Ontruzant®\) HCPCS Code Q5112: Billing Guidelines](#)**

TUESDAY, JUNE 9, 2020

Effective with date of service April 15, 2020, the Medicaid and NC Health Choice programs cover trastuzumab-dttb for injection, for intravenous use (Ontruzant®) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code Q5112 - Injection, trastuzumab-dttb, biosimilar, (Ontruzant®), 10 mg.

[More](#)

**[New Information Required in Applications for Individual Providers Enrolling in Medicaid and NC Health Choice](#)**

MONDAY, JUNE 8, 2020

Effective July 26, 2020, changes will be made to initial enrollment, re-enrollment, re-verification applications and manage change requests (MCRs) for individual providers (excluding disaster relief and Out of State Lite providers). The updates include the addition of a new page, as well as additional exclusion sanction questions.

[More](#)

**[SPECIAL BULLETIN COVID-19 #95: HIV Case Management Policy Allowances](#)**

FRIDAY, JUNE 5, 2020

NC Medicaid will allow temporary changes to Clinical Coverage Policy 12B for Written Physician Orders, Use of Remote Technology and Signature Requirements.

[More](#)

**[Understanding New Remittance Advice Refund Message](#)**

WEDNESDAY, JUNE 3, 2020

Beginning June 2020, the Remittance Advice will include a detailed explanation of any refund (Lump Sum / Miscellaneous Payment) issued to the provider. This message will be on the Financial Transactions page.

[More](#)

**[NC Medicaid Electronic Health Record Incentive Program Announcements](#)**

TUESDAY, JUNE 2, 2020

Program Year 2019 is Closed, NC-MIPS is Open for Program Year 2020, Program Year 2020 Webinar Series and The Security Risk Analysis (SRA).

[More](#)



***SPECIAL BULLETIN COVID-19 #94: Second Increase in Therapeutic Leave Days for ICF/IDD Facilities Due to COVID-19***

**TUESDAY, JUNE 2, 2020**

NC Medicaid is temporarily increasing the number of therapeutic leave days for Intermediate Care Facilities for Individuals with Intellectual Disabilities (ICF-IIDs) from 60 days to 120 days. This is a change from the previous increase to 90 days. NC Medicaid continues to waive the requirement of approval needed for more than 15 consecutive days per Clinical Coverage Policy 8E.

[More](#)